SBFM
Sunshine Biopharma Inc.Company Information
- Company Name
- Sunshine Biopharma Inc.
- CIK
- CIK0001402328
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SBFM: Nasdaq, SBFMW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SBFM
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-03-04
- Last sale
- —
- Shares purchased (TTM)
- 120,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 15,532
- Shares outstanding
- 1,365,324
- Ownership
- 1.14%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -5.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 14 | 7 | 9 | 9 | 10 | 8 | 10 | 12 | 12 | 17 | 16 | 19 | ||||||
| Accounts Receivable Net Current | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 3 | 4 | 3 | 3 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 31 | 25 | 27 | 28 | 28 | 24 | 26 | 26 | 26 | 29 | 25 | 25 | ||||||
| Inventory Net | 12 | 13 | 13 | 14 | 13 | 12 | 11 | 10 | 8 | 8 | 6 | 5 | ||||||
| Deposits Assets Current | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Deposit Assets | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 4 | 4 | - | 2 | - | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | ||||||
| Deferred Income Taxes And Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 34 | 28 | 30 | 31 | 32 | 29 | 31 | 30 | 29 | 32 | 27 | 28 | ||||||
| Accounts Payable Current | 5 | 5 | 6 | 6 | 5 | 5 | 6 | 4 | 5 | 4 | 3 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 7 | 6 | 5 | ||||||
| Accrued Income Taxes Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | ||||||
| Deferred Tax And Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 6 | 6 | 7 | 7 | 6 | 6 | 7 | 5 | 6 | 7 | 6 | 6 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 106 | 98 | 98 | 97 | 97 | 94 | 93 | 92 | 90 | 90 | 84 | 84 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 28 | 22 | 23 | 24 | 26 | 23 | 24 | 25 | 23 | 25 | 21 | 22 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | -0 | 0 | -1 | -1 | 0 | -1 | 0 | 1 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -78 | -76 | -75 | -73 | -72 | -70 | -69 | -67 | -66 | -65 | -64 | -63 | ||||||
| Liabilities And Stockholders Equity | 34 | 28 | 30 | 31 | 32 | 29 | 31 | 30 | 29 | 32 | 27 | 28 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | ||||||
| Common Stock Shares Issued | 2 | 5 | 5 | 5 | 5 | 3 | 3 | 2 | 1 | 1 | 0 | 26 | ||||||
| Shares Outstanding | 2 | 5 | 5 | 5 | 5 | 3 | 3 | 2 | 1 | 1 | 0 | 26 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSunshine Biopharma Inc. (SBFM) — SEC Financial Statements & Analysis
Sunshine Biopharma Inc. (SBFM) is a pharmaceutical preparations company, incorporated in CO. Sunshine Biopharma Inc. trades on Nasdaq as: SBFM, SBFMW. Sunshine Biopharma Inc. (SBFM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Sunshine Biopharma Inc. carries a market cap of $2.87M, a P/E ratio of -0.49x, a P/B ratio of 0.10x, a P/S ratio of 0.08x, an enterprise value of $-10.88M, and an EV/EBITDA multiple of 1.97x. On profitability, it posts a gross margin of 30.30%, an operating margin of -16.65%, a net margin of -16.50%, a Return on Equity (ROE) of -21.92%, a Return on Assets (ROA) of -17.78%, and a Return on Invested Capital (ROIC) of -37.44%. Per share, it reports EPS of $-4.27, diluted EPS of $-1.53, free cash flow per share of $-3.94, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -2.74% year-over-year, net income growth of -7.52% year-over-year, and EPS growth of -69.54% year-over-year. On the balance sheet, it maintains a current ratio of 5.46x, a quick ratio of 3.21x, working capital of $25.05M, a debt-to-equity ratio of 0.22x, a debt ratio of 0.18, an interest coverage ratio of -160.48x, free cash flow of $-5.37M (TTM), and net debt of $-13.75M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.87M
- P/E TTM
- -0.49x
- EPS TTM
- $-4.27
- P/B TTM
- 0.10x
- ROE TTM
- -21.92%
- ROA TTM
- -17.78%
- Debt To Equity
- 0.22x
- Free Cash Flow TTM
- $-5.37M
- Net Revenue TTM Growth 1Y
- -2.74%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Sunshine Biopharma Inc. in?
Sunshine Biopharma Inc. (SBFM) operates in the Pharmaceutical Preparations industry.
What exchange does SBFM trade on?
Sunshine Biopharma Inc. (SBFM) trades on the Nasdaq.
Where is Sunshine Biopharma Inc. incorporated?
Sunshine Biopharma Inc. is incorporated in CO.
When was Sunshine Biopharma Inc. (SBFM)'s most recent SEC filing?
Sunshine Biopharma Inc. (SBFM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is SBFM's market cap?
Sunshine Biopharma Inc. (SBFM) has a market capitalization of $2.87M as of 2026-06-30.
What is SBFM's EPS (earnings per share)?
Sunshine Biopharma Inc. (SBFM)'s trailing twelve month EPS is $-4.27 as of 2026-06-30.
What is SBFM's ROE (return on equity)?
Sunshine Biopharma Inc. (SBFM)'s trailing twelve month Return on Equity (ROE) is -21.92% as of 2026-06-30.
What is SBFM's ROA (return on assets)?
Sunshine Biopharma Inc. (SBFM)'s trailing twelve month Return on Assets (ROA) is -17.78% as of 2026-06-30.
What is SBFM's ROIC (return on invested capital)?
Sunshine Biopharma Inc. (SBFM)'s trailing twelve month Return on Invested Capital (ROIC) is -37.44% as of 2026-06-30.
What is SBFM's EV/EBITDA?
Sunshine Biopharma Inc. (SBFM)'s trailing twelve month EV/EBITDA is 1.97x as of 2026-06-30.